Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
Enhancing Outcomes in CSU: Insights From Barzolvolimab Phase 2 Data
Gil Yosipovitch, MD, discusses how barzolvolimab, a novel mast cell-depleting therapy targeting the KIT receptor, showed promising efficacy and safety results in a phase 2 trial for chronic spontaneous urticaria (CSU), achieving complete response in over 50% of patients within 12 weeks with sustained disease control lasting 28 weeks after treatment discontinuation.
EP. 2: Current and Emerging CSU Therapies
July 25th 2025An expert discusses how the evolving CSU treatment landscape includes H1 antihistamines as first-line therapy, omalizumab as second-line, and emerging treatments like dupilumab, remibrutinib, and barzolvolimab that target different mechanisms including mast cell depletion.
